07:21 AM EDT, 08/04/2025 (MT Newswires) -- Axsome Therapeutics ( AXSM ) reported a Q2 net loss Monday of $0.97 per diluted share, compared with a loss of $1.67 a year earlier.

Analysts polled by FactSet expected a loss of $1.13.

Total revenue for the quarter ended June 30 was $150 million, up from $87.2 million a year earlier.

Analysts polled by FactSet expected $138.3 million.

Axsome said it expects its current cash to be sufficient to fund operations into cash flow positivity.

Shares of the company rose more than 5% in recent Monday premarket activity.

Price: 109.09, Change: +6.07, Percent Change: +5.89